NASDAQ:HRTX Heron Therapeutics (HRTX) Stock Price, News & Analysis $1.80 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.73▼$1.8450-Day Range$1.73▼$3.6752-Week Range$0.50▼$3.93Volume2.04 million shsAverage Volume2.57 million shsMarket Capitalization$271.18 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Heron Therapeutics alerts: Email Address Heron Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside233.3% Upside$6.00 Price TargetShort InterestBearish23.87% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.53 out of 5 starsMedical Sector423rd out of 910 stocksPharmaceutical Preparations Industry189th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingHeron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Heron Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted23.87% of the outstanding shares of Heron Therapeutics have been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 14.9, which indicates bearish sentiment.Change versus previous monthShort interest in Heron Therapeutics has recently increased by 0.93%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHeron Therapeutics has received a 61.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Antiemetics and antinauseants (A04)", "Bupivacaine", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Heron Therapeutics is -1.96. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Heron Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for HRTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Heron Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Heron Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Heron Therapeutics Stock (NASDAQ:HRTX)Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Read More HRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRTX Stock News HeadlinesSeptember 3, 2024 | prnewswire.comHeron Therapeutics Announces Appointment of Brett Fleshman as Chief Business OfficerAugust 17, 2024 | nz.finance.yahoo.comHeron Therapeutics, Inc. (0J4V.L)September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 9, 2024 | seekingalpha.comHeron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | benzinga.comHeron Therapeutics (NASDAQ:HRTX) Stock Quotes, Forecast and News SummaryAugust 7, 2024 | markets.businessinsider.comHeron Therapeutics: Poised for Profitability Amid Growth CatalystsAugust 6, 2024 | investorplace.comHRTX Stock Earnings: Heron Therapeutics Misses EPS, Beats Revenue for Q2 2024August 6, 2024 | msn.comHeron Therapeutics GAAP EPS of -$0.06 misses by $0.02, revenue of $36.02M beats by $0.13MSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 6, 2024 | prnewswire.comHeron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial GuidanceAugust 6, 2024 | markets.businessinsider.comHeron Therapeutics is about to announce its earnings — here's what Wall Street expectsJuly 30, 2024 | prnewswire.comHeron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024July 25, 2024 | finance.yahoo.comHRTX Aug 2024 2.000 put (HRTX240816P00002000)July 25, 2024 | finance.yahoo.comWhile shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunateJuly 15, 2024 | prnewswire.comHeron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment SystemJuly 2, 2024 | prnewswire.comHeron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")June 27, 2024 | seekingalpha.comHeron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash ReservesMay 29, 2024 | finanznachrichten.deHeron Therapeutics, Inc.: Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ("VAN")See More Headlines Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRTX CUSIPN/A CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees300Year Founded1983Price Target and Rating Average Stock Price Target$6.00 High Stock Price Target$7.00 Low Stock Price Target$5.00 Potential Upside/Downside+233.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,560,000.00 Net Margins-35.29% Pretax Margin-35.29% Return on EquityN/A Return on Assets-21.68% Debt Debt-to-Equity RatioN/A Current Ratio2.38 Quick Ratio1.85 Sales & Book Value Annual Sales$136.36 million Price / Sales1.99 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-7.20Miscellaneous Outstanding Shares150,653,000Free Float141,011,000Market Cap$271.18 million OptionableOptionable Beta1.80 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Craig Alexander Collard (Age 58)CEO & Director Ms. Ira Duarte (Age 55)Executive VP & CFO Mr. Ryan CraigVice President of MarketingMr. Sean T. Ristine (Age 54)Senior Vice President of Human Resources Mr. Robert Sullivan (Age 46)Senior VP of Oncology Care Franchise & Commercial Operations Dr. William P. Forbes Pharm. D. (Age 62)Pharm.D., Executive VP & Chief Development Officer Jeff CohnExecutive Director, Assistant General Counsel & Assistant SecretaryMore ExecutivesKey CompetitorsMersana TherapeuticsNASDAQ:MRSNGeneration BioNASDAQ:GBIONGM BiopharmaceuticalsNASDAQ:NGMRevance TherapeuticsNASDAQ:RVNCPacira BioSciencesNASDAQ:PCRXView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Bought 11,602 shares on 8/19/2024Ownership: 0.008%Clearline Capital LPSold 1,280,938 shares on 8/16/2024Ownership: 0.993%AQR Capital Management LLCBought 568,238 shares on 8/15/2024Ownership: 0.403%Caxton Associates LPBought 202,157 shares on 8/15/2024Ownership: 0.134%The Manufacturers Life Insurance Company Bought 6,328 shares on 8/15/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions HRTX Stock Analysis - Frequently Asked Questions How have HRTX shares performed this year? Heron Therapeutics' stock was trading at $1.70 at the start of the year. Since then, HRTX shares have increased by 5.9% and is now trading at $1.80. View the best growth stocks for 2024 here. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) issued its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.02. The biotechnology company had revenue of $36.02 million for the quarter, compared to analyst estimates of $35.35 million. Does Heron Therapeutics have any subsidiaries? Heron Therapeutics subsidiaries include Heron Therapeutics B.V.. Who are Heron Therapeutics' major shareholders? Heron Therapeutics' top institutional investors include Orchard Capital Management LLC (1.49%), Renaissance Technologies LLC (1.32%), Marshall Wace LLP (1.17%) and Congress Park Capital LLC (1.05%). Insiders that own company stock include Adam Morgan, Ira Duarte, William P Forbes, Kimberly Manhard and Waage Christian. View institutional ownership trends. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT) and Immunomedics (IMMU). This page (NASDAQ:HRTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.